BioSpace News Archive

Tricida, Inc. announced that it has entered into a debt facility with Hercules Capital, Inc., a leader in customizing debt financing for companies in the life sciences and technology-related markets.

Globus Medical, Inc., a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2022 after the market close on Tuesday, November 8, 2022.

Ascentage Pharma (6855.HK) today announced that it will release results from the Phase I first-in-human study of APG-1387, the company’s investigational inhibitor of apoptosis protein (IAP) antagonist, in patients with chronic hepatitis B (CHB), in an oral presentation at the 73th American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022).

dentalcorp Holdings Ltd. announced today that it will release its third quarter 2022 financial results before market open on November 9, 2022.

Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”) announced today that the Company will be hosting booths this week at IDWeek 2022 in Washington, D.C., and at Asia Health/Medlab Asia in Bangkok, Thailand.

City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient to receive its novel, promising cancer medicine AOH1996 is doing well.

Nabsys, the pioneer in electronic whole-genome mapping, announced that Justin Bingham has joined the company as its Chief Commercial Officer.

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the publication of Phase 3 clinical data in the Journal of the American Medical Association (JAMA), highlighting that the clinical benefits of investigational therapeutic SER-109 for preventing recurrent C. difficile infection (rCDI) were apparent as early as two weeks post-treatment and sustained for at least 24 weeks.

According to Nova one advisor, the global Magnetic Resonance Imaging market size was valued at USD 7.9 billion in 2022 and is predicted to hit USD 10.17 billion by 2030 with a registered CAGR of 4.9% during the forecast period 2022 to 2030